8 Amitriptyline Alternatives for Chronic Migraine

Amitriptyline is one of the oldest and cheapest options for preventing migraine, and for some people it works well. For others, the tradeoffs are hard to live with: morning grogginess, dry mouth, constipation, and weight gain often show up before any drop in migraine days does.

If you have chronic migraine and amitriptyline is not the right fit, the list of alternatives in 2026 is longer and better studied than it has ever been. This guide covers eight of them, what the research actually shows for each in chronic migraine specifically, and who each option tends to suit.

Key Takeaways

• Amitriptyline is used off-label for migraine prevention, and its guideline evidence grade comes from trials in episodic migraine rather than chronic migraine.
• A systematic review of chronic migraine prevention found no amitriptyline trials that met its quality standards, so the chronic-migraine evidence base for the drug is thin.
• CGRP-targeting medications have the strongest chronic-migraine-specific evidence, reducing monthly migraine days by about two days more than placebo.
• Behavioral programs such as Lin Health offer a non-drug path for people whose main problem with amitriptyline is side effects, working alongside medical care rather than replacing it.
• Do not stop amitriptyline on your own. Tricyclics are tapered rather than stopped abruptly, so any switch should be planned with a clinician.

Why People Look for Alternatives to Amitriptyline

Amitriptyline is a tricyclic antidepressant. The FDA has approved it for major depressive disorder only, which means migraine prevention is an off-label use, common and accepted, but off-label all the same.

The evidence behind it is real but modest. Pooling the available placebo-controlled trials, amitriptyline raises responder rates (relative risk 1.60 for a 50 percent reduction in attacks), which works out to roughly 165 more responders per 1,000 people treated. In the single trial reporting it, that translated to about 1.2 fewer migraine days per month. The reviewers were blunt about the quality of the underlying trials, describing the results as "far from robust."

There are three practical reasons people go looking for something else.

• The evidence is for episodic migraine, not chronic. The neurology guideline that grades amitriptyline as "probably effective" covers episodic migraine prevention. When one research team reviewed drugs for chronic migraine specifically, they reported "no eligible studies" for amitriptyline, candesartan, or propranolol, because the older trials predated the modern chronic migraine definition or were too small.
• Side effects drive people off it. Drowsiness, dry mouth, constipation, tachycardia, weight gain, and QT interval prolongation are the commonly reported effects. Across trials, about 50 more per 1,000 stopped amitriptyline because of side effects compared with placebo, and a 2025 network analysis of oral preventives found roughly doubled adverse events versus placebo.
• Age changes the calculation. The American Geriatrics Society's 2023 Beers Criteria list amitriptyline among medications to avoid in older adults, citing strong anticholinergic activity, sedation, and orthostatic hypotension.

None of this means amitriptyline is a bad drug. It means it is one option among many, and if it is not working for you, there is a well-mapped landscape to move to.

One important caution before you read further: tricyclics should be tapered gradually, not stopped cold. Talk with your prescriber before changing anything.

How We Chose These Alternatives

Every option below is FDA-approved, FDA-cleared, or supported by recent peer-reviewed evidence. Because chronic migraine (15 or more days of headache a month) has a different evidence base than episodic migraine, we flag which type each option was actually studied in. Where the evidence is strong, we say so. Where it is thin or contested, we say that too.

1.A Brain-First Behavioral Program

For people whose main problem with amitriptyline is how it makes them feel, a non-drug option is the natural first place to look. That is where Lin Health sits, and it is the option we cover first.

Lin Health is not medication, physical therapy, or injections. It is a structured program delivered by trained recovery coaches, supported by an app with guided lessons and practices. Care is covered by insurance in high-coverage states, and it starts with a same-day callback, so people often begin within days rather than waiting months for a specialist appointment.

How it works

The approach is based on the science of how pain and other persistent symptoms can become "stuck." After an initial trigger, the brain's alarm system can keep firing in the absence of ongoing danger, and over time that pattern becomes learned. Lin Health's program works to retrain that response by addressing the fear, emotions, and thought loops that keep the alarm active, an approach grounded in brain-based pain science and the research on centrally generated pain rather than pain from tissue damage.

What the evidence shows

Behavioral approaches have migraine-specific research behind them. A 2025 evidence review of 50 adult trials found that cognitive behavioral therapy, relaxation training, and mindfulness-based therapy each may lower attack frequency by roughly one day per month, at a low strength of evidence. The same review found the evidence insufficient to draw conclusions about acceptance and commitment therapy or hypnotherapy in adults, so the honest framing is that some behavioral components are better supported than others.

Lin Health's program is based on that behavioral evidence base and on neuroplastic pain research, applied alongside medical migraine care rather than in place of it.

Who it tends to suit

Adults who stopped amitriptyline or another preventive because of side effects, who have gotten partial relief from medication and want to address what is left, or who want to work on the nervous-system side of chronic migraine. It pairs with a clinician's prevention plan rather than replacing it. Lin Health's chronic migraine condition guide goes deeper on the model.

2. Behavioral Therapies (CBT, Relaxation, Mindfulness)

Beyond a structured program, the individual behavioral therapies are worth understanding on their own. Cognitive behavioral therapy, relaxation training, and mindfulness-based therapy each may reduce migraine frequency by around a day a month in adults, at low strength of evidence.

One nuance is often reported incorrectly. In a well-known trial in adults with 4 to 20 migraine days a month, mindfulness-based stress reduction did not beat education on attack frequency, the study's main question. It did produce significant improvements in disability, quality of life, self-efficacy, pain catastrophizing, and depression that held to 36 weeks. So mindfulness is better supported for how much migraine disrupts your life than for how often attacks happen. Note that trial enrolled people below the chronic migraine threshold, so applying it to chronic migraine involves some extrapolation.

Biofeedback sits in a genuinely unsettled place: the 2025 evidence review rated it insufficient, while a narrower 2025 meta-analysis found it beat waitlist control but not active treatments.

Who it tends to suit: People who want to address stress, fear of the next attack, and the emotional weight of chronic migraine, usually alongside medical prevention. Lin Health's program draws on CBT-based approaches and migraine-specific practices such as working with attack triggers.

3. CGRP Monoclonal Antibodies

CGRP monoclonal antibodies are migraine-specific medications given by injection or infusion. The four available agents are erenumab, fremanezumab, galcanezumab, and eptinezumab.

This is the class with the strongest chronic-migraine-specific evidence. A 2026 systematic review of 43 trials in chronic migraine found reductions of 1.8 to 2.3 days of monthly migraine beyond placebo across the four antibodies, at high to moderate certainty. Fremanezumab sat at the low end of that range and eptinezumab at the high end. In its current position statement, the American Headache Society says CGRP-targeting therapies are a first-line option for prevention and that starting them should not require failing older drugs like amitriptyline first.

Worth knowing: the American College of Physicians took a different position in 2025, keeping amitriptyline first-line for episodic migraine after judging the clinical differences between treatments small enough that cost and patient preference became the deciding factors. The American Headache Society publicly disagreed. Both positions are current. If your clinician suggests trying an older drug first, insurance rules and this debate are often why.

Who it tends to suit: People who want the strongest chronic-migraine evidence base and are comfortable with a monthly self-injection, or a quarterly infusion in the case of eptinezumab.

4. Gepants (Oral CGRP Blockers)

Gepants block the same pathway as the antibodies, but in pill form. Atogepant is the one that matters most here: in April 2023 the FDA approved it for chronic migraine, making it the first oral CGRP receptor antagonist approved for both episodic and chronic migraine. In the 2026 chronic migraine review, atogepant performed in the same range as the injectable antibodies, at about two migraine days beyond placebo.

Rimegepant is a different story. It is approved for prevention in episodic migraine, and in chronic migraine specifically that same review concluded it probably has no effect. That distinction matters if you have chronic migraine.

Who it tends to suit: People who want migraine-specific prevention but prefer a daily pill to an injection.

5. OnabotulinumtoxinA (Botox) Injections

Botox has been FDA-approved for chronic migraine since 2010 and is given as injections every 12 weeks across the head and neck. It is approved for chronic migraine only, not episodic.

Its place in 2026 is more modest than it once looked. In the 2026 chronic migraine review, botulinum toxin reduced monthly migraine days by about 1.3 days beyond placebo at low certainty, less than the CGRP options, and it carried a threefold higher rate of stopping treatment because of side effects. In a small head-to-head trial against amitriptyline in chronic daily migraine, the two performed similarly, with no significant difference in responder rates.

Who it tends to suit: People with chronic migraine who prefer a treatment they think about four times a year rather than daily, particularly when insurance favors it.

6. Other Oral Preventive Medications

If you want to stay with a daily pill but move off amitriptyline, four oral preventives carry the neurology guideline's top grade for migraine prevention: topiramate, the beta-blockers propranolol and metoprolol, and divalproex sodium. Venlafaxine is often mentioned alongside them, but it sits at the same grade as amitriptyline, one tier down.

Two caveats keep this honest. First, that evidence base is built on episodic migraine, the same limitation amitriptyline has. Second, in chronic migraine specifically, the 2026 review found the trials of topiramate, valproate, and propranolol were sparse and high-risk. These drugs are widely used and inexpensive, but a switch within this category is a switch in side-effect profile more than a clear step up in chronic-migraine evidence.

Who it tends to suit: People who want a low-cost daily option, or who have a second condition (such as high blood pressure) that one of these can address at the same time.

7. Non-Invasive Neuromodulation Devices

Neuromodulation devices use mild electrical or magnetic stimulation to influence the nerves involved in migraine. Several are FDA-cleared, including Cefaly (trigeminal nerve stimulation), Nerivio (remote electrical neuromodulation), gammaCore (vagus nerve stimulation), and SAVI Dual (single-pulse magnetic stimulation).

For prevention specifically, the International Headache Society's 2025 guideline issued weak recommendations only, and only for gammaCore, Cefaly, and Nerivio. SAVI Dual's recommendation from that guideline covers acute attacks, not prevention. Evidence quality across the devices ranged from very low to moderate. The upside is real, though: they are drug-free, well tolerated, and have no drug interactions, which makes them a reasonable add-on when medication side effects are the problem.

Who it tends to suit: People who want a drug-free option, usually layered onto other prevention, and who can accept that the evidence is still developing.

8. Lifestyle Foundations: Exercise, Sleep, and Nutraceuticals

These rarely replace medical prevention, but they support whatever else you choose, and they are the layer a preventive pill does not touch.

• Aerobic exercise. Recent meta-analyses suggest regular aerobic exercise may lower migraine days and pain intensity, with benefit accumulating as total exercise volume increases. The same analysis offers a preliminary routine of around three 30-minute sessions a week, which its authors say needs confirmation in larger trials.
• Sleep. A 2026 review of sleep and migraine found digital CBT for insomnia was followed by fewer migraine days in one included study, though that study had no control group. In-person CBT for insomnia improved sleep without a significant effect on migraine counts. The authors called sleep-targeted migraine research a genuine gap. Lin Health has practical sleep guidance for people living with persistent symptoms.
• Magnesium, riboflavin, and CoQ10. These have supportive but limited evidence for migraine prevention. Note that the neurology guideline that originally graded them was formally retired in 2015 over safety concerns about a different supplement, so treat the old letter grades with care.
• Butterbur: avoid. It once carried the highest supplement grade, but it contains hepatotoxic pyrrolizidine alkaloids and is no longer recommended by neurology guidelines.

Supplements interact with medications and are not risk-free, so run doses past a clinician first.

Who it tends to suit: Nearly everyone, as a foundation under whichever primary prevention you choose.

How Lin Health Helps With Chronic Migraine

If amitriptyline left you choosing between migraine days and side effects, the nervous-system side of chronic migraine is often the underused lever. That is where Lin Health focuses.

Lin Health's approach is based on the science of central sensitization and neuroplastic pain: the idea that a persistent alarm in the brain and nervous system can be retrained over time. Rather than a book or a self-guided app, the program pairs you with a recovery coach for live sessions and between-session support, backed by structured modules drawn from behavioral approaches including CBT and ACT.

What tends to matter most for people coming off a preventive medication:

• No medication involved. Nothing to titrate, and no anticholinergic side effects to trade against migraine days.
• Insurance-covered. Lin Health is in-network with most major insurance plans, with the broadest coverage in Colorado, Texas, Florida, California, and New York. Coverage varies by plan and state, so eligibility is checked before you start.
• Short wait times. A same-day callback checks eligibility, so people often start within days.
• Specialized. Coaches focus on chronic pain and persistent symptoms, not general talk therapy.

People have used this kind of approach to regain daily function, and Lin Health works with headache-focused practices including the NY Headache Center. For more on the non-drug side of prevention, see Lin Health's overview of chronic migraine prevention approaches.

If amitriptyline has not been the right fit, a brain-first behavioral program may be worth exploring alongside your medical care for chronic migraine. Check your migraine eligibility with Lin Health. Wait times are short, often a same-day call, and many patients in covered states pay nothing out of pocket.

FAQ

What can I take instead of amitriptyline for chronic migraine?

The options with the strongest chronic-migraine evidence are the CGRP-targeting medications: the injectable antibodies erenumab, fremanezumab, galcanezumab, and eptinezumab, plus the oral gepant atogepant. Botox, other oral preventives, neuromodulation devices, and behavioral programs are also used. Your prescriber will weigh your history and insurance coverage.

Why does amitriptyline cause so many side effects? 

Amitriptyline blocks several receptor systems beyond the ones relevant to migraine. That produces anticholinergic effects such as dry mouth and constipation, plus sedation and weight gain. In trials, about 50 more people per 1,000 stopped it because of side effects compared with placebo.

Is amitriptyline FDA-approved for migraine? 

No. The FDA has approved amitriptyline for major depressive disorder. Using it to prevent migraine is an off-label use. That is common and accepted in headache care, but it means the FDA has not reviewed the drug for this purpose.

Can I just stop taking amitriptyline? 

No, not on your own. Clinical guidance is to taper gradually to avoid withdrawal rather than stop a tricyclic abruptly. Ask your prescriber to plan a taper, ideally at the same time you start the next option, so you are not left without prevention in between.

Does anything non-drug actually work for chronic migraine? 

Some approaches have real support. Cognitive behavioral therapy, relaxation training, and mindfulness may each reduce attack frequency by around a day a month in adults, at low strength of evidence. Regular aerobic exercise and better sleep may also help. These generally work well alongside medical prevention rather than in place of it.

Is Lin Health covered by insurance? 

Lin Health is in-network with most major insurance plans, with the broadest coverage in Colorado, Texas, Florida, California, and New York. Coverage varies by plan and state. A callback, often the same day, checks your eligibility before you start.

What counts as chronic migraine? 

Chronic migraine means headache on 15 or more days per month for more than three months, with migraine features on at least eight of those days. Fewer than 15 headache days per month is classified as episodic migraine, which is what most preventive drug trials studied.

The Bottom Line

Amitriptyline is inexpensive and familiar, but it is off-label for migraine, its evidence comes mostly from episodic migraine trials, and its side effects are the reason many people go looking for something else. In 2026 the alternatives are stronger: CGRP medications have the strongest chronic-migraine evidence, devices and lifestyle changes add drug-free support, and brain-first behavioral programs like Lin Health give people a non-drug path that works alongside medical care and is covered by insurance in several states. Because the right combination depends on your pattern and your history, the next step is a conversation with your clinician about what to move to, and how to taper safely.

This article is for informational purposes and is not medical advice. Treatment names and approvals reflect information available as of July 2026. Talk with a qualified healthcare provider before starting, stopping, or changing any migraine treatment, including amitriptyline.